AI Capital Markets - Among 2022 top picks * Quipt Home Medical Corp. (QIPT-X) with a “buy” rating and $13.50 target. Average: $12.68.
Ms. Stellick: “QIPT had a steady stream of small acquisitions in 2021, which translated to a modest share price appreciation of 10 per cent for the year. However, beneath the surface the Company was preparing for more rapid expansion, which we anticipate will enable scaling up the pace of M&A as QIPT tries to beat its guidance of US$180-190-million run-rate revenue with US$38-43M run-rate Adj. EBITDA at year end on its way to US$250-million in run-rate revenue with US$63-million-plus Adj. EBITDA. Constructive steps were taken in 2021, including uplisting to the Nasdaq, requesting an increase in the size of the undrawn credit facility to US$100-million to allow for some leverage, and a key hire to lead the M&A and Integration Team.”